Trou­bled Im­muno­Cel­lu­lar slash­es costs, jobs in re­struc­tur­ing; Ac­cel­er­at­ed Phar­ma dumps strug­gling IPO ef­fort

⇨ LA-based Im­muno­Cel­lu­lar Ther­a­peu­tics $IMUC is push­ing through a cost-cut­ting pro­gram, slash­ing staff and fa­cil­i­ties in the process. Two board mem­bers are al­so leav­ing the trou­bled com­pa­ny. A few weeks ago the floun­der­ing biotech was forced to call a halt to pa­tient as­sign­ments for its Phase III study af­ter run­ning short of cash to com­plete the job.

⇨ A day af­ter Ul­tragenyx was forced to scrap one of its Phase III ef­forts, the biotech and its part­ners at Ky­owa Hakko Kirin have filed a mar­ket­ing ap­pli­ca­tion at the FDA for buro­sum­ab, a new ther­a­py for X-Linked Hy­pophos­phatemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER